Repository logo
 

Validation of a 5-Year Prognostic Model for Parkinson's Disease.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

BACKGROUND: A simple prognostic model was previously developed to predict the probability of recently-diagnosed patients reaching negative outcomes (postural instability, dementia or death) in a 5-year period. OBJECTIVES: To validate this model in an independent cohort and establish utility at later time points. METHODS: Validation was performed using data collected in an incident cohort at baseline, 2 and 4 years. Predicted negative outcome probabilities were compared to actual 5-year outcomes. RESULTS: The model, based on age, MDS-UPDRS axial score and 60-second animal fluency, predicted poor 5-year outcome when applied at baseline, (area under the curve (AUC) 0.80), 2 years (AUC 0.82) and 4 years (AUC 0.71). Power calculations showed that selecting a subgroup with prognostic score >0.5 reduced the sample size required for a disease-modifying trial. CONCLUSIONS: This 5-year prognostic model has good accuracy when employed up to 4 years from diagnosis and may help stratification for disease-modifying trials.

Description

Journal Title

Mov Disord Clin Pract

Conference Name

Journal ISSN

2330-1619
2330-1619

Volume Title

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellcome Trust (203151/Z/16/Z)
MRC (MR/W029235/1)
Medical Research Council (MC_PC_17230)
Medical Research Council (MR/R007446/1)
The PICNICS study has received funding from the Cure Parkinson’s Trust, the Van Geest Foundation, the Medical Research Council (MRC) and Parkinson’s UK. This work was also supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312). M.C. was supported by Centre for Parkinson-Plus. R.A.B. was supported by the Wellcome-MRC-Stem Cell Institute (Cambridge 203151/Z/16/Z). C.H.W.G. is supported by the MRC (MR/W029235/1) and the (NIHR) Cambridge Biomedical Research Centre (NIHR203312). KM Scott is currently an employee of AstraZeneca but was involved in this work prior to that employment.